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Abstract
Background:  Transcription-induced chimerism, a mechanism involving the transcription and
intergenic splicing of two consecutive genes, has recently been estimated to account for ~5% of the
human transcriptome. Despite this prevalence, the regulation and function of these fused
transcripts remains largely uncharacterised.
Results: We identified three novel transcription-induced chimeras resulting from the intergenic
splicing of a single RNA transcript incorporating the two neighbouring 3p21.3 tumour suppressor
locus genes, RBM6 and RBM5, which encode the RNA Binding Motif protein 6 and RNA Binding
Motif protein 5, respectively. Each of the three novel chimeric transcripts lacked exons 3, 6, 20 and
21 of RBM6 and exon 1 of RBM5. Differences between the transcripts were associated with the
presence or absence of exon 4, exon 5 and a 17 nucleotide (nt) sequence from intron 10 of RBM6.
All three chimeric transcripts incorporated the canonical splice sites from both genes (excluding
the 17 nt intron 10 insertion). Differential expression was observed in tumour tissue compared to
non-tumour tissue, and amongst tumour types. In breast tumour tissue, chimeric expression was
associated with elevated levels of RBM6 and RBM5 mRNA, and increased tumour size. No protein
expression was detected by in vitro transcription/translation.
Conclusion: These results suggest that RBM6 mRNA experiences altered co-transcriptional gene
regulation in certain cancers. The results also suggest that RBM6-RBM5 transcription-induced
chimerism might be a process that is linked to the tumour-associated increased transcriptional
activity of the RBM6 gene. It appears that none of the transcription-induced chimeras generates a
protein product; however, the novel alternative splicing, which affects putative functional domains
within exons 3, 6 and 11 of RBM6, does suggest that the generation of these chimeric transcripts
has functional relevance. Finally, the association of chimeric expression with breast tumour size
suggests that RBM6-RBM5 chimeric expression may be a potential tumour differentiation marker.
Background
Transcription-induced chimerism, resulting from the tran-
scription and intergenic splicing of two consecutive genes,
was previously thought to be a rare event in mammals.
Recent studies, however, incorporating systematic in silico
analyses of ESTs and cDNAs in the NCBI databases, con-
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clude that as much as 5% of the human transcriptome is
comprised of chimeric sequences [1]. These fusion tran-
scripts are generated from tandem genes that are physi-
cally located within ~50 kb of each other, the median
distance being ~8.5 kb [2]. Although transcription-
induced chimeras can function to (1) expand functional
protein diversity, (2) alter transcriptional regulation, (3)
inhibit transcription of the two participating genes, or (4)
inhibit transcription of putative functional intergenic
sequences (such as small miRNA sequences), the mecha-
nism regulating its occurrence remains elusive [2].
RBM6 (RNA Binding Motif protein 6) [GenBank Acces-
sion Number: NM_005777] was first identified by posi-
tional cloning from a small cell lung carcinoma
homozygous deletion region at the 3p21.3 tumour sup-
pressor locus [3], and, in parallel, as a differentially
expressed transcript during granulocyte differentiation
[4]. The gene covers ~137 kilobases (kb) and has 21
exons. RBM6 is immediately adjacent to, telomeric to, and
11 kb from, the RBM5 gene. While the RBM6 gene has
been shown to be either deleted or disrupted in some lung
cancers [5], RBM6 mRNA was recently found to be signif-
icantly upregulated in breast cancer [6]. In addition, the
RBM6 protein was first isolated in an autologous antibody
screen from a patient with adenocarcinoma of the lung,
demonstrating an association between elevated levels of
RBM6 protein and cancer [7]. Of significance to the work
reported herein, a novel trans-fusion protein incorporat-
ing the amino-terminal region of RBM6 (breaking 21
amino acids into exon 3) with the carboxy-terminal
region of colony stimulating factor 1 receptor (CSF1R)
was recently reported in acute megakaryoblastic leukemia
[8].
RBM6 pre-mRNA is alternatively spliced to produce at
least five variants [3,7,9]. RBM6A, B, C and D differ only
in relation to which alternate sequence from intron 2 is
incorporated between exons 2 and 3. A fifth splice variant,
RBM6∆6, is identical to the predominant transcript,
RBM6A, but lacks exon 6. Timmer and colleagues [3]
demonstrated that expression of this RBM6∆6 transcript
was much higher in normal lung tissue than in lung can-
cer tissues, suggesting that removal of exon 6, which con-
tains one of two consensus RNA recognition motif (RRM)
domains within the protein, is important for tumour sup-
pression. It was recently reported that expression of either
RBM6 or RBM6∆6 mRNA and RBM10v2 mRNA (encod-
ing a protein with ~30% identity to both RBM6 and
RBM5), was downregulated and highly correlated in rela-
tion to a number of clinicopathologic parameters nor-
mally associated with poor breast cancer prognosis,
suggesting that the coordinated expression, and/or alter-
native splicing, of RBM6 and RBM10v2 is an important
aspect of breast tumorigenesis [10].
The RBM5 (RNA Binding Motif protein 5)/LUCA-15/H37
gene covers approximately 30 kb of genomic DNA and
has 25 exons. RBM5  [GenBank Accession Number:
NM_005778] generates at least four RNA splice variants,
RBM5, RBM5∆6, RBM5+6 and RBM5+5+6 [9]. All of these
transcripts are ubiquitously expressed, albeit to differing
levels, in normal tissues. Expression of RBM5 mRNA is
downregulated in tumour tissue compared to normal tis-
sue [11-16], although our recent study reports that expres-
sion of RBM5 mRNA is marginally upregulated (p  =
0.063) and protein is significantly upregulated (p = 1.43 ×
10-8) in breast tumour tissue [6]. Numerous functions
have been ascribed to RBM5  gene products, including
tumor suppression [11,17], apoptosis modulation [17-
19], cell cycle regulation [20] and RNA binding [5,12],
however, the mechanism of action of the full-length
RBM5 protein is only just beginning to be delineated [17].
In the study described herein, we set out to investigate the
existence of an RBM6-RBM5 chimeric transcript whose
expression, or protein product, regulated expression of
RBM6 and RBM5. Here we report the unexpected identifi-
cation of not one but three novel non-coding RBM6-
RBM5 chimeric mRNA transcripts, which were differen-
tially expressed in tumour versus non-tumour tissue and
whose expression was not associated with decreased
RBM6 or RBM5 mRNA expression levels.
Results
Identification of three novel RBM6-RBM5 chimeric 
transcripts
RBM6 and RBM5 map to the short arm of human chro-
mosome 3 and are separated by ~11 kb (Figure 1). Since
transcription-induced chimeras can be generated from
genes which are physically located up to 50 kb from each
other (the median distance being ~8.5 kb [2]), we decided
to investigate the existence of such a chimeric transcript
from this locus. Nested PCR was performed on cDNA gen-
erated from total RNA from the human breast adenocarci-
noma cell line MDA-MB-231. The outer nested primers
were located within exon 8 of RBM6 and exon 7 of RBM5,
and the inner nested primers were located within exon 17
of RBM6 and exon 4 of RBM5. In order to eliminate arti-
facts from template switching events (which are normally
attributed to sequence similarities at intron boundaries),
thermostable reverse transcriptase was used [21]. An ~550
base-pair (bp) amplicon was observed (Figure 2Ai), which
sequencing revealed lacked exons 20 and 21 of RBM6 and
exon 1 of RBM5 (Figure 2Aii).
Having determined, by nested RT-PCR, that an RBM6-
RBM5 chimeric transcript did exist, we then focused on
obtaining a full-length open reading frame. Since during
the course of our investigations we found that the ampli-
con was expressed most highly in the human Jurkat T lym-BMC Genomics 2007, 8:348 http://www.biomedcentral.com/1471-2164/8/348
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phoblastic leukemia cell line and in human skeletal
muscle tumour tissue, we used total RNA from Jurkat cells
and skeletal muscle tumour as templates. Outer nested
primers specific for exon 1 of RBM6 and exon 7 of RBM5
were used in combination with inner nested primers spe-
cific to exon 1 of RBM6 and exon 5 of RBM5. The experi-
ment was repeated several times. Two different amplicons
were identified in the Jurkat cells (chimeric transcripts 1
and 3, Figure 2B), while a third unique amplicon was
identified in the skeletal muscle tumour (chimeric tran-
script 2, Figure 2B). All amplicons were sequenced. The
different transcripts were termed RBM6-RBM5 chimeric
transcript 1 (Jurkat cell origin), RBM6-RBM5 chimeric
transcript 2 (skeletal muscle origin) and RBM6-RBM5 chi-
meric transcript 3 (Jurkat cell origin). The common char-
acteristic of all three chimeric transcripts was a lack of
exons 3, 6, 20, and 21 of RBM 6, and exon 1 of RBM5. The
difference between all three chimeric transcripts related to
the presence or absence of exons 4 and 5 and a 17 nt inser-
tion from RBM6 intron 10: chimeric transcript 1 lacked
RBM6 exons 3 to 6; chimeric transcript 2 lacked RBM6
exon 3 and exon 6, and included the additional 17 nt
from RBM6 intron 10, and; chimeric transcript 3 only
lacked RBM6 exon 3 and exon 6 (Figure 2C).
Differential expression of the RBM6-RBM5 chimeric 
transcripts in non-tumour and tumour tissue
To this point, RBM6-RBM5 chimeric expression was
observed in the human breast adenocarcinoma cell line
MDA-MB-231, T lymphoblastic leukemia Jurkat cell line
and skeletal muscle tumour, all representing malignant
cancers. We therefore decided to investigate the relation-
ship between RBM6-RBM5 chimeric expression and
malignancy by examining expression in non-malignant
tissue.
Nested PCR was carried out in various tissues, including
non-tumour and tumour, using the same primers as men-
tioned above to identify the ~550 bp amplicon. (Note,
since the PCR product generated by these primers was
common to all three transcripts, this experiment did not
discriminate between the specific chimeric transcripts.)
Interestingly, chimeric expression was never observed in
non-tumour tissue samples. In addition, expression was
not consistently observed in all tumour tissue types:
expression was observed in lung, ovary, skeletal muscle,
lymph node, pancreas and breast but not in skin, spleen,
uterus, bone, brain, prostate or testis tumour tissue (Fig-
ure 3A, B and 3C). Numerous cancer cell lines were also
examined for expression of the chimeric transcripts,
including breast (MDA-MB-231, MCF-7, BT-474), hemat-
opoietic (Jurkat subclone JKM1, TF-1, Raji, K562), lung
(GLC20), skin (A431) and cervical (HeLa). GLC20 is a
small cell lung cancer cell line known to harbour a 440 kb
homozygous deletion at 3p21.3 [22], and was therefore
selected as a negative control for RBM6-RBM5 chimeric
transcript detection. Nested RT-PCR results indicated that
RBM6-RBM5 chimeric transcription occurred in all cancer
cell lines, irrespective of tissue of origin, excluding the
GLC20 negative control.
Further analysis of RBM6-RBM5 transcription-induced
chimeric expression in tumour samples revealed that
expression in the tumour tissue was not solely dependent
on either tumour type or tissue type (Table 1). For
instance, two different large cell lung carcinomas had dif-
ferent chimeric profiles, demonstrating not only that not
all lung tumours are positive for chimeric expression, but
that not all lung tumours of the same type (large cell), are
positive. Likewise for the malignant fibrous histiocytoma
of skeletal muscle, non-Hodgkin's lymphoma, insuli-
noma of the pancreas and cystadenoma of the ovary.
These results suggest that some additional factor, such as
tumour grade or differentiation status, plays a role in
RBM6-RBM5 chimeric expression. Unfortunately, insuffi-
cient pathological information was available for the lung,
ovarian, skeletal muscle, lymph or pancreatic tumours to
evaluate possible criteria which might account for expres-
sion differences. Fortunately, the breast tumour samples
were provided with more pathological information (refer
to Table 2). There were no apparent expression differences
related to grade, lymph node involvement, estrogen or
progesterone receptor status, HER2 status or donor age;
however, there appeared to be a threshold tumour size
after which RBM6-RBM5 chimeric transcript expression
was detectable (Table 2). All three chimeric transcript
expressing breast tumour samples (#1, 2, 3) were the larg-
Genomic organisation of RBM6 and RBM5 Figure 1
Genomic organisation of RBM6 and RBM5. A. Diagram 
outlining the orientation and spatial relationship between 
RBM6 and RBM5. The size of both genes, in relation to the 
distance between them, is indicated in base-pairs. Vertical 
numbers represent chromosomal markers. Sideways arrows 
represent translation start sites. B. Scale diagram comparing 
RBM6 intragenic distances to the RBM6/RBM5 intergenic dis-
tance. Vertical bars represent exons, solid horizontal lines 
represent introns and the dotted line represents the inter-
genic region. The sideways arrows represent the translation 
start sites, within exon 2 of both genes.
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Identification of an RBM6-RBM5 chimeric transcript by nested RT-PCR Figure 2
Identification of an RBM6-RBM5 chimeric transcript by nested RT-PCR. Ai. Agarose gel of the nested RT-PCR 
result from MDA-MB-231 mRNA, using outer primers RBM6E8F and RBM5E7R and inner primers RBM6E17F and RBM5E4R, 
showing the ~550 bp amplicon in lane 2. Lane 1: DNA ladder (1 kb, Invitrogen). Aii. Schematic of the amplified 550 bp frag-
ment, showing the splicing out of RBM6 exons 20 and 21, and RBM5 exon 1. Blue boxes indicate exons of RBM6, orange boxes 
indicate exons of RBM5, dotted lines delineate site of intragenic splicing. B. Agarose gel of the nested RT-PCR results for full-
length RBM6-RBM5 chimeric transcripts, using outer primers RBM6Fb and RBM5E7R and inner primers RBM6Fc and 
RBM5E5R. The three chimeric transcripts are from different experiments. Chimeric transcripts 1 and 3 were amplified from 
Jurkat cells, whereas chimeric transcript 2 was amplified from skeletal muscle tumour. M1: 1 kb DNA ladder (Invitrogen). M2: 
1 kb DNA ladder (New England Biolabs). Arrow identifies the faint amplicon observed for chimeric transcript 3. C. Schematic 
detailing the splicing patterns associated with the three chimeric transcripts. Numbered boxes represent exons, dotted lines 
represent alternative splice sites. Arrows: delineate putative translation start codons of longest ORFs. Stop signs: represent 
putative translation stop codons of the longest ORFs. The triangle in chimeric transcript 2 indicates the site of the 17 nucle-
otide insertion (represented by the red line) from RBM6 intron 10. Not drawn to scale.
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est in our five-sample cohort (4.5, 6.0 and 3.0 cm in the
largest dimension, respectively). The sample with incon-
sistent chimeric transcript expression was 2.7 cm in its
largest dimension, and the chimeric transcript negative
tumour was 2.5 cm in its largest dimension. This observa-
tion suggests that tumour size, as a measure of breast
tumour differentiation status, may be an important
parameter of RBM6-RBM5 chimeric expression. A larger
sample size, however, is required to confirm this hypoth-
esis.
Protein analysis of the RBM6-RBM5 chimeric transcripts
While evidence points to the fact that transcription-
induced chimerism occurs quite frequently in the human
genome [2], only a few fusion proteins have actually been
identified, only a portion of which have a known function
[23-25].
Sequence analysis of the three chimeric transcripts
revealed the longest ORF initiating, for each, within exon
7 of RBM6 but terminating at different premature termi-
nation codons (PTC) in each of the three transcripts (Fig-
ure 2C). In chimeric transcript 1, the PTC occurred within
exon 2 of RBM5, resulting in a putatively ~62 kDa chi-
RBM6-RBM5 chimeric transcript expression Figure 3
RBM6-RBM5 chimeric transcript expression. Chimeric expression was examined using nested RT-PCR on tissue or cell 
line mRNA. A. Expression in purchased human tissue samples: lung – large cell carcinoma; ovary – cystadenoma; skeletal mus-
cle – malignant fibrous histiocytoma, poorly differentiated; skin – malignant melanoma; spleen – malignant lymphoma; uterus – 
adenocarcinoma, well differentiated. B. Expression in purchased human tissue samples: bone – osteoblastic osteosarcoma; 
brain – astrocytoma, moderately differentiated; lymph node – non-Hodgkin's lymphoma of tonsil; pancreas – insulinoma; pros-
tate – adenocarcinoma, moderately differentiated; and testis – seminoma. C. Expression in three tumour samples from the 
Ontario Cancer Research Network, and an unmatched purchased non-tumour sample. D. Expression in human cancer cell 
lines: GLC20 – small cell lung carcinoma; MDA-MB-231 – pleural effusion of a breast adenocarcinoma; JKM1 – Jurkat T lym-
phoblastic leukemia subclone; MCF-7 – pleural effusion of a breast adenocarcinoma; TF-1 – erythroblastic leukemia; A431 – 
epidermoid carcinoma; HeLa – cervical carcinoma; BT-474 – invasive ductal breast carcinoma; K-562 – chronic myelogenous 
leukemia; Raji – Burkitt's lymphoma. NT: non-tumour tissue, T: tumour tissue.BMC Genomics 2007, 8:348 http://www.biomedcentral.com/1471-2164/8/348
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meric protein of 521 amino acids (aa), in frame with
RBM6 but including an additional four aa from RBM5: the
5'-untranslated region (UTR) was 186 nt long. Chimeric
transcripts 2 and 3 both contained PTCs situated in
RBM6, putatively encoding two novel, truncated RBM6
proteins. The presence of the intron 10 insertion in chi-
meric transcript 2 created a PTC located within exon 11 of
RBM6, generating an ORF of 199 aa, putatively encoding
an ~24 kDa protein with high homology to RBM6 but
with six novel, additional aa from the 17 nt insertion. Chi-
meric transcript 3 contained a point mutation in exon 18,
generating a PTC and thus resulting in an ORF putatively
encoding an ~58 kDa protein of 482 aa. The 5'-UTR of chi-
meric transcripts 2 and 3 was 346 nt. Significantly, the
presence of long 5'-UTRs (>100 nt) and premature termi-
nation codons in each of these long ORFs, and the lack of
a Kozak sequence surrounding the exon 7 ATG codon [26]
suggested that either translation initiation would be
inhibited or the chimeric transcripts would be degraded
by nonsense-mediated decay [27,28]. If translation initi-
ated within RBM6 exon 2 for each of the chimeric tran-
scripts, thereby utilizing the partial Kozak sequence-
associated translation initiation codon for RBM6 protein,
premature termination would occur in all three tran-
scripts. In chimeric transcript 1 the PTC would occur
within RBM6 exon 7, resulting in a putatively ~2 kDa pro-
tein of 17 aa. In chimeric transcripts 2 and 3 the PTCs
would occur within RBM6 exon 4, resulting in a putatively
~4 kDa protein of 33 aa. Since premature termination
codons were noted for all of the above described open
reading frames, we postulated that no protein product,
particularly no RBM6-RBM5 "fusion" protein, would
actually be encoded by these novel chimeric transcripts.
To investigate this, we examined protein production from
each of the chimeric transcripts. Since the mRNA expres-
sion levels were relatively low (only being detectable
using nested RT-PCR), an in vitro transcription/translation
system was used rather than an immunoblot technique.
Chimeric cDNAs were first cloned into the pCR®II TOPO®
vector, then incubated in a rabbit reticulocyte lysate with
radioactive methionine. As shown in Figure 4, no
polypeptide products were observed for any of the chi-
meric transcripts, from either orientation. Positive con-
Table 2: Clinicopathological parameters of breast tumour samples
Tumour 
sample
Chimeric 
transcript 
status
Tumour 
grade
Lymph node 
metastases
Estrogen 
receptor 
status
Progesterone 
receptor 
status
HER2 status Patient age 
(yrs)
Tumour size 
(cm)
T1 + 3 + + - + 33 4.5
T 2 +3+++?8 1 6 . 0
T3 + 2 + + - - 71 3.0
T 4 + / - 3+++-5 4 2 . 7
T 5-2+++?8 6 2 . 5
+ : positive expression
- : negative expression
? : indeterminate expression
Table 1: Summary of expression of RBM6-RBM5 chimeric transcripts in various tumour and non-tumour tissues
Breast Lung Lymph node Pancreas Ovary Skeletal muscle
N o n - t u m o u r  1 ------
N o n - t u m o u r  2 ------
N o n - t u m o u r  3 ------
Tumour 1 + + a + c + e + f + h
Tumour 2 + - a - c - e - f - h
Tumour 3 + - b - d - g
Tumour 4 +/-
Tumour 5 -
a: large cell carcinoma
b: squamous cell carcinoma
c: non-Hodgkin's lymphoma
d: T cell Hodgkin's lymphoma
e: insulinoma
f: cystadenoma
g: adenocarcinoma, poorly differentiated
h: malignant fibrous histiocytoma, pooly differentiated
(+): positive for expression; (-): negative for expression. Blank grids indicate no corresponding cDNA was examinedBMC Genomics 2007, 8:348 http://www.biomedcentral.com/1471-2164/8/348
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trols included pcDNA3.RBM10 for the T7-specific
reaction, producing the expected product of ~120 kDa
(and two additional products, always visualized), and the
antisense pcDNA3.RBM5(-) construct for the SP6-specific
reaction, producing the expected ~115 kDa major prod-
uct. These results suggested that the RBM6-RBM5 chimeric
transcripts are non-coding mRNAs.
RBM6-RBM5 chimeric transcript expression in relation to 
RBM6 and RBM5
Since no RBM6-RBM5 protein product was observed, it
was tempting to speculate that either (1) the novel chi-
meric transcripts function at the mRNA level, or (2) the
chimeric RNA's are "non-functional", but the physical act
of chimeric transcription functions to inhibit, or at least
downregulate, expression of the two individual genes,
RBM6 and RBM5. We therefore initiated our investigation
by examining the relationship between expression of
RBM6 and RBM5 in tumour samples that were either chi-
meric positive or negative. If RBM6-RBM5 non-coding
mRNAs are indeed non-functional, and the physical act of
chimeric expression is involved in the regulation of RBM6
and/or RBM5 expression, then expression of both genes in
the chimeric positive tumours would be expected to
decrease in relation to the chimeric negative tumours. If,
however, RBM6-RBM5 non-coding mRNAs are indeed
functional, then the expected outcome on RBM6 and/or
RBM5 expression would be less predictable.
In vitro transcription/translation of chimeric transcript cDNAs Figure 4
In vitro transcription/translation of chimeric transcript cDNAs. In vitro transcription/translation results using the T7 
and SP6 TNT ®quick coupled transcription/translation system in the presence of [35S] methionine. Products were electro-
phoresed through a denaturing polyacrylamide gel. pcDNA3.RBM10 and the antisense pcDNA3.RBM5(-) constructs were used 
as positive controls for the T7 and SP6 polymerases, respectively. Reaction minus template ("no template") was used as a neg-
ative reaction control.BMC Genomics 2007, 8:348 http://www.biomedcentral.com/1471-2164/8/348
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SYBR green based quantitative PCR (QPCR) technology
was used in the analyses. Since lack of exon 3 was
uniquely associated with the RBM6-RBM5 transcription-
induced chimeras (refer to Figure 2C and Figure 5), exon
3-specific primers were used to differentiate between non-
chimeric and chimeric RBM6 transcripts. Likewise, RBM5
exon 1-specific primers were used to differentiate between
non-chimeric and chimeric RBM5 transcripts. Two paired
skeletal muscle samples were chosen, one that expressed
the chimeric transcripts and one that did not. Two breast
tumour tissue samples were also chosen, one that
expressed the chimeric transcripts (T1, Figure 3C) and one
that did not. Commercial normal breast cDNA was used
for normalization.
Interestingly, the results showed that elevated levels of
chimeric transcript were in fact associated with elevated
levels of RBM6 and RBM5. RBM6 was highly expressed in
the chimeric positive skeletal muscle tumour compared to
the chimeric negative skeletal muscle tumour. The raw
data are presented as Table 3, showing an ~1.5-fold
increase of RBM6 mRNA expression levels in the chimeric
negative tumour sample (compared to non-tumour sam-
ple), but an ~14-fold increase of RBM6 in the chimeric
positive tumour sample (compared to non-tumour sam-
ple). A similar trend was observed in the breast tissues (an
~16-fold increase in RBM6 expression in the chimeric neg-
ative tumour sample and an ~25-fold increase in the chi-
meric positive tumour sample), supporting an expression
correlation between RBM6 expression and that of the
RBM6-RBM5 chimeras, and demonstrating that the phe-
nomenon was not tissue-specific.
One interpretation of the observation of a positive corre-
lation between RBM6-RBM5 chimeric expression and
RBM6 expression is that chimeric expression represents a
small fraction of tumour-associated aberrant "run-off" or
"leakage" RBM6 transcription events [2]. If this were the
case, one might still expect to see a decrease in RBM5
mRNA expression, since the promoter of RBM5 is inoper-
able due to chimera-associated splicing. As shown in
Table 4, however, RBM5 mRNA expression levels, in
breast tissue, were found to be higher in chimeric positive
tumours than chimeric negative tumours, further suggest-
ing that the process of transcription-induced chimerism at
this locus is not responsible for repressing expression of
either of the two putative tumour suppressor genes RBM6
and  RBM5. It is therefore hypothesized that the three
novel RBM6-RBM5 transcription-induced chimeras are
functional non-coding RNAs, whose role is not one of
RBM6 and/or RBM5 transcription regulation.
Discussion
We previously reported that RBM6 mRNA expression was
significantly upregulated in human breast tumour tissue
compared to non-tumour tissue [6]. Here we report that
RBM6 mRNA expression was also elevated in skeletal
muscle tumour tissue compared to normal, from ~1.5-
fold in one tumour to ~14-fold in a different tumour. The
larger increase in RBM6 expression levels was associated
with the expression of three novel RBM6-RBM5 transcrip-
tion-induced chimeras, each lacking exons 3, 6, 20, and
21 of RBM6 and exon 1 of RBM5, but differing in the pres-
ence or absence of exon 4, exon 5 and a 17 nt sequence
from intron 10 of RBM6. All three transcripts incorpo-
rated the canonical splice sites from both genes (excluding
the 17 nt intron 10 insertion). According to Akiva and col-
leagues [2], the most abundant transcription-induced chi-
meric splicing pattern, occurring in 80 % of the events,
removes any exon of the upstream gene and the first exon
of the downstream gene. Each of the three novel RBM6-
RBM5 transcription-induced chimeras falls within this
category, and is, therefore, not a rare form of "chimerism".
Alternative splice variants of RBM6 Figure 5
Alternative splice variants of RBM6. The five RBM6 
alternative splice variants, showing deleted exons, differen-
tially inserted regions from within intron 2, putative transla-
tion start sites (arrows) and putative stop codons (stop 
signs) [7]. Boxes represent exons and are not drawn to scale. 
Exon 3 (which is present in all RBM6 variants but absent in all 
RBM6-RBM5 chimeric transcripts) is depicted in blue, while 
exon 6 (which is differentially spliced in RBM6 variants and 
the RBM6-RBM5 chimeras, and contains the first of two RRM 
domains) is depicted in red. The forward and backward 
hatched boxes drawn as alternatively spliced sequences from 
intron 2, represent two different sequences, while the solid 
black box represents the same sequence in both RBM6C and 
RBM6D.
1 2 3 4 5 6 7 8 9 1 01 11 21 31 41 51 6 1 71 81 92 0 2 1
RBM6A
RBM6B
RBM6C
RBM6D
RBM6'6
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The RBM6-RBM5 chimeric transcripts appear to be differ-
entially expressed in tumour compared to non-tumour
samples. While no expression was detected in non-
tumour samples, chimeric transcripts were observed in
carcinoma (breast, lymph node, lung, ovary and pan-
creas) and sarcoma (skeletal muscle) samples. The differ-
ential chimeric expression patterns observed in tumours
of the same tissue type, for instance non-Hodgkin's versus
T cell Hodgkin's lymphoma or large cell versus squamous
cell lung carcinoma, may not reflect tumour cell origin-
specific expression patterns so much as the differentiation
status of that individual tumour sample. This hypothesis
is supported by our observations in the breast tumour
samples, where chimeric expression appeared to be asso-
ciated with a threshold tumour size.
For the three novel RBM6-RBM5 transcription-induced
chimeric transcripts identified, it was interesting to note
that each was generated by differential splicing of exons
incorporating putative functional consensus sequences,
e.g., the novel 20-repeat hexamer sequence within exon 3
(hypothesized to play a role in RNA interactions [7]), the
RNA recognition motif (RRM) within exon 6 (an RNA
binding domain [29]), and the G-patch domain associ-
ated with exon 20 (involved in RNA splicing [30]). In
addition, differential splicing within RBM6 intron 10 in
chimeric transcript 2 resulted in elimination of the second
RBM6 RRM domain within exon 11. It was therefore inter-
esting to speculate that the transcription-induced chimer-
ism at the RBM6 locus was important to the generation of
novel functional RBM6-related proteins with different
mechanisms of action; however, no novel fusion protein
was generated and there was no reduction in either RBM6
or RBM5 mRNA expression levels associated with RBM6-
RBM5 chimeric expression. The consistent splicing pat-
terns associated with the chimeras, all revolving around
exons containing putatively significant functional
domains, suggests that chimerism at this site, or at least
altered expression of RBM6 and perhaps RBM5, is an
important and regulated event. The importance of RBM6
tumour-associated expression regulation remains to be
determined.
Conclusion
Transcription-induced chimeras of the neighboring genes
RBM6 and RBM5 were identified in human tumour tis-
Table 4: Relative expression levels of RBM5 in chimeric positive versus chimeric negative tumour samples compared to non- tumour
RBM5 (mean ± SD) Control (S28) (mean ± SD) normalized RBM5 fold change in tumour 
compared to non-tumour
Breast Tissue
tumour
chimeric transcript (+) 0.073 ± 0.001 0.013 ± 0.001 5.615 35.31
chimeric transcript (-) 0.041 ± 0.005 0.029 ± 0.004 1.413 8.886
non-tumour 0.017 ± 0.003 0.107 ± 0.005 0.159 1
(+) : chimeric transcript positive, (-) : chimeric transcript negative.
Table 3: Relative expression levels of RBM6 in chimeric positive versus chimeric negative tumour samples compared to non-tumour
RBM6 (mean ± SD) Control (S28) 
(mean ± SD)
normalized RBM6 fold change in tumour compared 
to non-tumour
Breast Tissue
tumour
chimeric transcript (+) 0.403 ± 0.008 0.073 ± 0.007 5.521 24.43
chimeric transcript (-) 0.243 ± 0.012 0.066 ± 0.01 3.682 16.3
non-tumour 0.051 ± 0.006 0.226 ± 0.06 0.226 1
Skeletal Muscle
tumour: chimeric transcript (+) 0.0488 ± 0.001 0.0489 ± 0.005 0.998 14.06
non-tumour 0.005 ± 0.0003 0.070 ± 0.01 0.071 1
tumour: chimeric transcript (-) 0.063 ± 0.01 0.297 ± 0.058 0.212 1.52
non-tumour 0.022 ± 0.002 0.158 ± 0.02 0.139 1
(+) : chimeric transcript positive, (-) : chimeric transcript negative.BMC Genomics 2007, 8:348 http://www.biomedcentral.com/1471-2164/8/348
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sues. No novel fusion proteins were encoded by any of the
RBM6-RBM5 chimeras, but chimeric expression was posi-
tively correlated with expression of RBM6 and RBM5
mRNA. The functional significance and regulation of this
event remain to be elucidated; however, RBM6-RBM5 chi-
meric transcripts could prove to be useful tumour differ-
entiation markers, although more extensive expression
analyses are required to confirm these observations.
GenBank Accession Numbers deposited:
RBM6-RBM5 chimeric transcript 1: EF566883
RBM6-RBM5 chimeric transcript 2: EF566884
RBM6-RBM5 chimeric transcript 3: EF566885
Methods
Cell lines and tissue samples
RNA from the following cell lines was used to generate the
cDNA for PCR expression studies: GLC20 (generously
provided by Charles Buys, Gröningen University, The
Netherlands), MDA-MB-231 (ATCC# HTB-26), Jurkat
(JKM1) [31], MCF-7 (the kind gift of David Seldon, Bos-
ton University, U.S.A.), TF-1 (ATCC# CRL-2003), HeLa
(provided by Hoyun Lee, HRSRH) and BT-474 (ATCC #
HTB-20). cDNA for the following cell lines was purchased
(BioChain Institute, Inc., CA, U.S.A.): A431, K562 and
Raji. cDNA for all of the tissue samples, except the breast
tumours, was also purchased (BioChain Institute, Inc.,
CA, U.S.A.). Five breast tumour samples were obtained
from the Ontario Cancer Research Network Pilot Distri-
bution Project. Each of these was classified as invasive
mammary carcinoma of no special type. Three non-
tumour breast samples were purchased (BioChain Insti-
tute, Inc., CA, U.S.A.).
RNA isolation, DNase treatment and reverse-transcription
Total RNA was isolated from the GLC20, MDA-MB-231,
JKM1, MCF-7, TF-1, HeLa and BT-474 cell lines, and the
breast tumour tissues. RNA was isolated from the cell lines
using the RNeasy kit (Qiagen, U.S.A.) and from the breast
tissue using TRI-Reagent (Molecular Research Center, Inc.,
U.S.A.), according to the manufacturer's instructions. For
the breast tumour tissue RNA isolation, the tissue and the
tissue pulverizer (Beckman) were cooled in liquid nitro-
gen for 5 min, then 500 mg of tissue were pulverized and
dissolved in 1 ml of TRI-Reagent by passing through a
series of increasingly smaller-bore needles. Phase separa-
tion was achieved with the addition of chloroform, fol-
lowed by centrifugation. RNA was precipitated from the
aqueous layer using isopropanol. RNA pellets were
washed with 75% ethanol, air-dried and resuspended in
DEPC (Sigma)-treated water. RNA quantity and quality
were determined using a bioanalyzer (Agilent Technolo-
gies).
To hydrolyze contaminating DNA in the RNA prepara-
tions, 1 µg of RNA was incubated with 1 µl of amplifica-
tion-grade DNase I (Invitrogen) and 1 µl of 10× DNase
buffer in a final volume of 10 µl at room temperature for
15 min, then 1 µl of 25 mM EDTA solution was added and
the reaction stopped by heating at 65°C for 10 min. Fol-
lowing DNase treatment, 1µg of total RNA was reverse
transcribed using the Superscript II kit (Invitrogen),
according to the manufacturer's instructions. Briefly, 1 µl
of T20-VN (500 ng/µl) and 1 µl dNTP (10 mM) were
added to 10 µl of the above DNase treated RNA, incubated
at 65°C for 5 min, then chilled on ice. Then, 4 µl 5× first-
strand buffer, 2 µl dithiothreitol (DTT), 1 µl RNase Out
and 1 µl Superscript reverse transcriptase were added to
the reaction. Following a 1 hour incubation, the reaction
was stopped by heating at 70°C for 15 min. The newly
transcribed cDNA was used directly for PCR amplifica-
tion. For amplification of the full-length chimeric tran-
scripts, reverse transcription was carried out using the
thermostable enzyme supplied with the transcriptor first-
strand cDNA synthesis kit (Roche), according to the man-
ufacturer's instructions.
Primers
The following primers were used, based on GeneBank
Accession Numbers NM_005777 (RBM6) and
NM_005778 (RBM5):
RBM6Fb: AGGCTGAGGAGAAGGAGGAG
RBM6Fc: AGGAGAAGGAGGAGCGGG
RBM6E8F: GCACCGATCTTCCTGTTCAT
RBM6E17F: GCTGTCAGACCTGCACAAG
QRBM6E3F1: TCTTGGGCGGCAAGACA
QRBM6E3R1: GGCTTCCTGGCAGCCTATG
RBM5E4R: CAGTGACGAGAGGGAGAGCAAGA
RBM5E5R: CGGATGTGAGGCTGATGAAGAGGA
RBM5E7R: TCAAGGAAAGCACATTGCAA
QRBM5E1F1: CGGAGGCGCCATTTTGA
QRBM5E1R1: GAAGCAGCAGTAGCGGTTCTGBMC Genomics 2007, 8:348 http://www.biomedcentral.com/1471-2164/8/348
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Nested PCR amplification
Two different sets of nested PCR reactions were carried
out, one for the identification of a short, internal chimeric
product, and the other for the identification and isolation
of a chimeric product containing an entire putative ORF.
The nested PCR reactions were carried out in an iCycler
thermal cycler (BioRad). 2 µl of each cDNA were used as
template in a total volume of 50 µl. Reactions contained
200  µm each of deoxynucleoside triphosphate (dATP,
dCTP, dGTP and dTTP), 2.5 units of Taq polymerase and
0.2 µM of each primer. For identifying the shorter chi-
meric transcript, RBM6E8F and RBM5E7R were used as
forward and reverse primers, respectively, in the first
round of amplification. First round amplification was car-
ried out at 95°C for 3 min, followed by 35 cycles of 94°C
for 30 sec, 55°C for 30 sec and 72°C for 2 min 20 sec, fol-
lowed by 72°C for 10 min. The second round of amplifi-
cation was carried out using RBM6E17F and RBM5E4R as
forward and reverse primers, respectively, with 2 µl of the
first round PCR reaction as template. This second round
of amplification was performed at 95°C for 3 min, fol-
lowed by 40 cycles of 94°C for 30 sec, 55°C for 30 sec and
72°C for 45 sec, followed by 72°C for 10 min. Electro-
phoresis of the PCR products was performed through a
2% agarose gel containing 0.1 µg/ml ethidium bromide.
For the longer chimeric transcripts, RBM6Fb and
RBM5E7R were used as forward and reverse primers,
respectively, for the first round of amplification. The first
round of amplification was carried out at 95°C for 3 min,
followed by 35 cycles of 94°C for 30 sec, 55°C for 30 sec
and 72°C for 4 min, followed by 72°C for 10 min. The
second round of amplification was carried out by using
inner primers RBM6Fc and RBM5E5R, with 2 µl of the first
round PCR reaction as template. This second round of
amplification was performed at 95°C for 3 min, followed
by 40 cycles of 94°C for 30 sec, 55°C for 30 sec and 72°C
for 4 min, followed by 72°C for 10 min. Electrophoresis
of the PCR products was performed through a 0.8 % aga-
rose gel containing 0.1 µg/ml ethidium bromide.
Quantitative real-time PCR
To determine the relative-fold expression of RBM6 and
RBM5 in tumour tissue with or without RBM6-RBM5 chi-
meric transcript expression, quantitative real-time PCR
(QPCR) was performed. RBM6 levels were measured
using primers (QRBM6E3F1 and QRBM6E3R1) located
within exon 3, since exon 3 sequence was present in each
of the known RBM6 RNA splice variants but absent from
each of the RBM6-RBM5 chimeric transcripts. RBM5 levels
were measured using primers (QRBM5E1F1 and
QRBM5E1R1) located within exon 1, since exon 1
sequence was present in each of the known RBM5 RNA
splice variants but absent from each of the RBM6-RBM5
chimeric transcripts. Real-time PCR was carried out using
SYBR green (Applied Biosystems) technology and an ABI
Prism 7900HT Sequence Detection System (Applied Bio-
systems). In a 25 µl reaction, 12.5 µl of a 2× SYBR Green
Master Mix, 7.5 µl of a 2 µM stock of each primer and 5 µl
of 1:8 diluted cDNAs were combined. The PCR pro-
gramme incorporated denaturation at 95°C for 10 min,
followed by 40 cycles of amplification at 95°C for 15 sec,
55°C for 15 secs and 72°C for 30 secs. All samples were
analyzed in triplicate, and the data were normalized to the
S28 internal control.
TA cloning and sequencing
The three different full-length RBM6-RBM5 chimeric tran-
scripts were amplified by nested PCR, as described above,
using the two sets of primers RBM6Fb/RBM5E7R and
RBM6Fc/RBM5E5R. The three PCR products, ranging
between 2.1–2.4 kb, were gel purified using a gel purifica-
tion kit (Qiagen) and cloned into the pCR®II-TOPO vector
using the TOPO TA dual promoter cloning kit (Invitro-
gen), according to the manufacturer's instructions. The
clones obtained were confirmed by sequencing (Mobix-
lab, McMaster University, Canada), and the sequences
compared to GenBank sequences through BLAST [32].
In vitro transcription/translation
The  in vitro transcription/translation experiments were
performed using the T7 and SP6 TNT® Quick Coupled
Transcription/Translation Systems (Promega) in the pres-
ence of [35S] methionine (Perkin Elmer), according to the
manufacturer's instructions. Template plasmids were the
three pTA constructs, containing the three different chi-
meric transcript cDNAs, and putatively encoding proteins
as large as 62 kDa (chimeric transcript 1), 24 kDa (chi-
meric transcript 2) and 58 kDa (chimeric transcript 3).
The pcDNA3.RBM10 and pcDNA3.RBM5(-) constructs
were used as positive controls for the T7 and SP6 polymer-
ases, respectively. 0.5 µg of each plasmid was used per 25
µl reaction, which was incubated at 30°C for 90 min. 7.5
µl of each reaction was separated by 10% SDS-PAGE. Gels
were then transferred to PVDF membrane (Pall, Gelman
Sciences) and exposed to Hyperfilm (GE Heathcare).
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